BOSTON and LONDON, Sept. 7, 2016 /PRNewswire/ -- CSA Medical held a mini-symposium at the ERS Conference on Tuesday, September 6, 2016 in London, England. The symposium highlighted early data from its feasibility study utilizing the RejuvenAir® Metered Cryospray™ System, which is under development for the treatment of chronic bronchitis.
The symposium raised awareness of the ongoing efforts to develop a liquid nitrogen spray cryotherapy treatment for patients with chronic bronchitis. The discussions detailed the histology of goblet cell production and inflammation in chronic bronchitis patients, and demonstrated how spraying liquid nitrogen on the surface of the airway lumen may result in regeneration of healthy tissue.
To date, eleven chronic bronchitis patients have been enrolled in the European safety and feasibility trial (NCT02483637), and have had treatment limited to their right lower lobe. The treatment was conducted without any intro-operative adverse events. The sixty day follow-up results of these eleven patients have shown a positive impact on these patients, with an average Saint George Respiratory Questionnaire (SGRQ) score improvement of 7.9 points. An improvement of 4 points is considered clinically meaningful according to peer reviewed literature. These patients will continue to be followed, and will receive the remainder of their treatment as we embark on phase B of the trial.
"These early results are promising, as they demonstrate the safety of the procedure and the potential for a positive impact to the lives of chronic bronchitis patients. We will continue to monitor the patients for further SGRQ score improvements after all treatable portions of their lungs have been treated," said Ellen Sheets, MD, CEO CSA Medical.
Chronic bronchitis is a subset of Chronic Obstructive Pulmonary Disease (COPD). A chronic bronchitis diagnosis is defined by cough with productive sputum of three months duration for two consecutive years. In addition to a chronic inflammation, cough and increased production of mucus, chronic bronchitis may or may not present with obstruction/partially blocked airways due to swelling and excess mucus in the bronchi, or shortness of breath (dyspnea).
About CSA Medical
CSA Medical, Inc. develops and manufactures a proprietary interventional spray cryotherapy technology platform utilizing unique properties of liquid nitrogen spray delivered by a software driven device with specialty catheters that enable delivery of spray cryogen inside the body to flash freeze and destroy unwanted tissue allowing for a rejuvenative pattern of healing. CSA manufactures and distributes this technology in the USA as the truFreeze system which uses Liquid Nitrogen spray that has a boiling point of -196oC to ablate unwanted benign and malignant tissue. The RejuvenAir System is currently under clinical investigation and is not commercially available.
To learn more about our technology, please visit www.csamedical.com.
PRLog ID: www.prlog.org/12585273
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/csa-medical-presented-early-clinical-data-on-the-rejuvenair-metered-cryospray-system-at-the-european-respiratory-society-ers-conference-300324407.html
SOURCE CSA Medical